title: Long-term outcomes of intravitreal ranibizumab for choroidal neovascularization secondary to Best's disease: 3-year follow-up.
authors.forename: Oscar
authors.initials: O
authors.lastname: Ruiz-Moreno
authors.forename: Pilar
authors.initials: P
authors.lastname: Calvo
authors.forename: Blanca
authors.initials: B
authors.lastname: Ferrández
authors.forename: Clemencia
authors.initials: C
authors.lastname: Torrón
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002648:Child; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D057826:Vitelliform Macular Dystrophy / Q000150:complications*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab